AstraZeneca PLC (AZN)

32.86
0.19 0.57
NYSE : Health Care
Prev Close 33.05
Open 32.91
Day Low/High 32.86 / 33.17
52 Wk Low/High 26.97 / 35.04
Volume 4.56M
Avg Volume 6.04M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 83.62B
EPS 1.10
P/E Ratio 14.82
Div & Yield 0.90 (2.70%)

Latest News

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.

Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp

Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp

The company has spent $600 million weighing a potential breakup.

Cempra Is Ready to Run

Cempra Is Ready to Run

Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.

Phase III Combination Trial Of BYDUREON And FARXIGA Shows Significant Blood Sugar Reduction In Patients With Type 2 Diabetes

Phase III Combination Trial Of BYDUREON And FARXIGA Shows Significant Blood Sugar Reduction In Patients With Type 2 Diabetes

Positive results from the Phase III DURATION-8 trial demonstrated that BYDUREON (exenatide extended-release) for injectable suspension 2 mg once-weekly in combination with FARXIGA (dapagliflozin) 10 mg once-daily...

AstraZeneca (AZN) Stock Higher, Jefferies Upgrades

AstraZeneca (AZN) Stock Higher, Jefferies Upgrades

Jefferies increased AstraZeneca's (AZN) stock rating to 'buy' this morning.

Teva Discusses EpiPen Comps as Host of Generics Unveiled

Teva Discusses EpiPen Comps as Host of Generics Unveiled

The drug company has several generic drugs that will compete with the likes of Pfizer's Viagra and Valeant's Acanya.

Benralizumab Phase III Trials Show Positive Results In Severe Asthma

Benralizumab Phase III Trials Show Positive Results In Severe Asthma

Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and...

AstraZeneca Announces SYMBICORT Demonstrated Comparable Risk Of Serious Asthma-Related Events And Lower Risk Of Asthma Exacerbations Compared To Budesonide Alone

AstraZeneca Announces SYMBICORT Demonstrated Comparable Risk Of Serious Asthma-Related Events And Lower Risk Of Asthma Exacerbations Compared To Budesonide Alone

AstraZeneca today announced results from the SYMBICORT ® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol LABA (long-acting beta 2-adrenergic agonist) safety study showing patients with controlled and...

Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal

Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal

So says a proxy filing made after trading on Tuesday, as a couple of suitors included contingent value rights in their bids for the marketer of prostate cancer drug, Xtandi.

Big Pharma's Punishment in Court of Public Opinion

Big Pharma's Punishment in Court of Public Opinion

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

Big Pharma Has No Rx for Viral Social Media Reactions

Big Pharma Has No Rx for Viral Social Media Reactions

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.

Crude Oil, Health Care Team Up to Pull Wall Street Lower

Crude Oil, Health Care Team Up to Pull Wall Street Lower

A selloff in crude oil and health care stocks led Wall Street into the red on Wednesday.

Stocks Extend Decline as Crude Falls to One-Week Low

Stocks Extend Decline as Crude Falls to One-Week Low

Stocks hold slightly lower by mid-afternoon Wednesday as a greater build to inventories accelerates losses in crude oil.

European Markets Mixed as Volatility Hits 17-Month Low

European Markets Mixed as Volatility Hits 17-Month Low

Mining stocks pull down London's benchmark index.

Stocks Hold Losses as Crude Oil Extends Decline

Stocks Hold Losses as Crude Oil Extends Decline

Stocks hold slightly lower by mid-afternoon Wednesday as a greater build to inventories accelerates losses in crude oil.

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer is making another acquisition.

Stock Futures Little Changed in Wait for Friday's Yellen Speech

Stock Futures Little Changed in Wait for Friday's Yellen Speech

Stock futures remain close to the flatline on Wednesday as investors await a critical speech from Federal Reserve Chair Janet Yellen at the end of the week.

Pfizer Picks Up AstraZeneca's Antibiotics Business

Pfizer Picks Up AstraZeneca's Antibiotics Business

The deal could be worth $1.5 billion.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Pfizer buys antibiotics business from AstraZeneca; Tesla unveils Model S version that can go 300 miles on a single charge; U.S. stock futures rise slightly.

European Markets Steady; Italy Hit by Earthquake

European Markets Steady; Italy Hit by Earthquake

Central part of Italy hit by 6.2 magnitude earthquake.

Medivation Scores Premium in Sale to Pfizer

Medivation Scores Premium in Sale to Pfizer

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.

Crude Selloff, Health Care Rally Split Wall Street

Crude Selloff, Health Care Rally Split Wall Street

Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

4 Stocks to Avoid Amid the Mad 'Search for Yield'

4 Stocks to Avoid Amid the Mad 'Search for Yield'

There's a price to pay for low expectations.

Why AstraZeneca (AZN) Stock Is Higher Today

Why AstraZeneca (AZN) Stock Is Higher Today

On Friday, AstraZeneca (AZN) stock hit the price offered by Pfizer (PFE) in 2014, helped in part by Bristol-Myers' (BMY) failed lung cancer study.

AstraZeneca (AZN) Leads The Pack In Pre-Market Activity

AstraZeneca (AZN) Leads The Pack In Pre-Market Activity

Trade-Ideas LLC identified AstraZeneca (AZN) as a pre-market leader candidate

Pfizer Beats Estimates for Second-Quarter Revenue, Earnings per Share

Pfizer Beats Estimates for Second-Quarter Revenue, Earnings per Share

The world's largest pharma company, Pfizer, tops expectations and reaffirms guidance for the full year.